Ph+ ALL

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

5 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
olverembatinib	CHINA PHARMA HOLDINGS, INC. (CPHI)
tki	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
tki	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 1(1)

Drug	Company
olverembatinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Preclinical(1)

Drug	Company
BCR-ABL TKI	Theseus Pharmaceuticals, Inc. (THRX)

BioSniper tracks 5 drugs in development for Ph+ ALL across 3 companies.

There are 2 clinical trials targeting Ph+ ALL tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.